DE69937899D1 - Antikörper-serumprotein hybride - Google Patents

Antikörper-serumprotein hybride

Info

Publication number
DE69937899D1
DE69937899D1 DE69937899T DE69937899T DE69937899D1 DE 69937899 D1 DE69937899 D1 DE 69937899D1 DE 69937899 T DE69937899 T DE 69937899T DE 69937899 T DE69937899 T DE 69937899T DE 69937899 D1 DE69937899 D1 DE 69937899D1
Authority
DE
Germany
Prior art keywords
serum protein
antibody serum
protein hybrid
hybrid
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69937899T
Other languages
English (en)
Other versions
DE69937899T2 (de
Inventor
Bryan John Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Application granted granted Critical
Publication of DE69937899D1 publication Critical patent/DE69937899D1/de
Publication of DE69937899T2 publication Critical patent/DE69937899T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69937899T 1998-11-10 1999-11-10 Antikörper-serumprotein hybride Expired - Fee Related DE69937899T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9824632 1998-11-10
GBGB9824632.5A GB9824632D0 (en) 1998-11-10 1998-11-10 Biological compounds
PCT/GB1999/003747 WO2000027435A1 (en) 1998-11-10 1999-11-10 Antibody-serum protein hybrids

Publications (2)

Publication Number Publication Date
DE69937899D1 true DE69937899D1 (de) 2008-02-14
DE69937899T2 DE69937899T2 (de) 2008-12-24

Family

ID=10842195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69937899T Expired - Fee Related DE69937899T2 (de) 1998-11-10 1999-11-10 Antikörper-serumprotein hybride

Country Status (8)

Country Link
US (2) US7105160B1 (de)
EP (2) EP1808155A3 (de)
AT (1) ATE382370T1 (de)
AU (1) AU1062700A (de)
DE (1) DE69937899T2 (de)
ES (1) ES2299268T3 (de)
GB (1) GB9824632D0 (de)
WO (1) WO2000027435A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
EP1444264A4 (de) * 2001-10-17 2005-10-26 Pharmaceuticals Inc Faulk Verfahren und materialien zum targeting und zur beeinflussung ausgewählter zellen
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2260058A2 (de) 2008-04-07 2010-12-15 Ablynx N.V. Variable einzeldomänen gegen notch-signalwege
EP2313436B1 (de) 2008-07-22 2014-11-26 Ablynx N.V. Gegen multitarget-scavenger-rezeptoren und polypeptide gerichtete aminosäuresequenzen
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
KR20130066631A (ko) 2010-05-06 2013-06-20 노파르티스 아게 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법
ES2949159T3 (es) 2010-05-06 2023-09-26 Novartis Ag Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
WO2011144749A1 (en) 2010-05-20 2011-11-24 Ablynx Nv Biological materials related to her3
EP3578568A3 (de) 2010-11-08 2020-01-08 Ablynx N.V. Cxcr2-bindende polypeptide
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
RU2014122602A (ru) 2011-11-04 2015-12-10 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3541846A1 (de) 2016-11-16 2019-09-25 Ablynx NV T-zell-rekrutierende polypeptide mit fähigkeit zur bindung von cd123 und tcr-alpha/beta
CA3065630A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
EP3774917A4 (de) 2018-03-30 2022-01-19 Nanjing Legend Biotech Co., Ltd. Einzeldomänenantikörper gegen lag-3 und verwendungen davon
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749570A (en) * 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
JPH05507924A (ja) * 1990-07-03 1993-11-11 アクゾ・エヌ・ヴエー 免疫反応性化合物
CA2074945A1 (en) * 1990-11-30 1992-05-31 Atsushi Isoai Tumor cell invasion-inhibiting peptides, peptide complexes and cancer metastasis inhibitors
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
AU2823495A (en) * 1994-06-09 1996-01-04 Houston Biotechnology Incorporated Methods and compositions for modulation of wound healing
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
WO1997034631A1 (en) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
WO1998048845A1 (en) * 1997-04-29 1998-11-05 Nycomed Imaging As Method of demarcating tissue

Also Published As

Publication number Publication date
EP1128847B1 (de) 2008-01-02
ATE382370T1 (de) 2008-01-15
US7105160B1 (en) 2006-09-12
WO2000027435A1 (en) 2000-05-18
DE69937899T2 (de) 2008-12-24
AU1062700A (en) 2000-05-29
EP1128847A1 (de) 2001-09-05
ES2299268T3 (es) 2008-05-16
GB9824632D0 (en) 1999-01-06
EP1808155A3 (de) 2007-10-31
US20060263375A1 (en) 2006-11-23
EP1808155A2 (de) 2007-07-18

Similar Documents

Publication Publication Date Title
ATE382370T1 (de) Antikörper-serumprotein hybride
KR910001057A (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도
AU6264686A (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
AU563356B2 (en) Conjugate of enzyme and antibody
DE69430450D1 (de) Zell- und serum- proteinanker und konjugate
AU7366687A (en) Coupling agents for radiolabeling proteins
DE69033705D1 (de) Hybride immunglobuline
DE69020007D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
DE69434384D1 (de) Metalkomplexbildner
NO971059L (no) Modifiserte human-C3-proteiner
GB2278357B (en) Humanised antibodies directed against A33 antigen
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
IN172885B (de)
ATE122723T1 (de) Retinoblastoma-genprodukt-antikörper und deren verwendungen.
EP1191096A4 (de) Neues protein und dessen dns
FI971879A0 (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
BR9815776A (pt) Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA, S.A., BRUXELLES, BE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee